Last checked at 2 Jan 2019 07:00
HVIVO PLC
("hVIVO" or the "Company")
Directorate Change
2 January 2019
The Company confirms that, as previously announced, Graham Yeatman ceased to be a Director of hVIVO with effect from 31st December 2018.
Trevor Phillips, Executive Chairman of hVIVO, said: "Along with the rest of the Board, I would like to thank Graham for his many contributions to the Company during the last seven years and we all wish him well in his future endeavours."
For further information please contact:
hVIVO plc | |
Trevor Phillips (Executive Chairman) | +44 207 756 1300 |
Fleur Wood (EVP, Investor Relations & Communications)
|
|
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black / Michael Burke (Corporate Broking) | |
FTI Consulting | |
Simon Conway / Victoria Foster Mitchell | +44 203 727 1000 |
About hVIVO:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.